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Abstract
Background: Tryptophan hydroxylase-2 (TPH2) is the rate-limiting enzyme in the synthetic pathway for brain serotonin and
is considered key factor for maintaining normal serotonin transmission in the central neuron system (CNS). Gene-disease
association studies have reported a relationship between TPH2 and major depressive disorder (MDD) in different
populations, however subsequent studies have produced contradictory results.
Objectives: We performed a systematic overview and a meta-analysis with all available data up-to-date.
Methods: We scrutinized PubMed, Embase, HuGNet and China National Knowledge Infrastructure (CNKI ) and last update
was held on October 2011. We also searched the manuscripts and the supplementary documents of the published genome-
wide association studies in the field. Effect sizes of independent loci that have been studied in more than 3 articles were
synthesized using fixed and random effects models.
Results: We found 27 eligible articles that studied a total of 74 single nucleotide polymorphisms (SNPs). Finally, 12
independent loci were included in the meta-analysis. The synthesis of the data shown that two SNPs (rs4570625 and
rs17110747) were associated with MDD using fixed effects models. SNP rs4570625 had low heterogeneity and remained
significant using the more conservative random effects calculations with a summary OR=0.83 (95% CI: 0.73–0.96).
Conclusion: The current study identified a SNP (rs4570625) with strong epidemiological credibility; however more studies
are required to provide robust evidence for other weak associations.
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Introduction
Major depressive disorder (MDD) is one of the most common
psychiatric disorder [1]. According to the DSM-IV-TR (American
Psychiatric Association, 2000), the lifetime risk of major depressive
disorder varies from 10 to 25% for women and 5 to 12% for men
in community samples. Prevalence rates appear to be unrelated to
marital status, education, income, or ethnicity. More than 50% of
the individuals who have had a single major depressive disorder
episode are expected to have a second episode.
Although the etiology of the disorder has not been well
recognized, a genetic component has been found. Twin studies
indicate that the heritability of MDD is 0.36 to 0.70 [2–7] and the
riskofMDDinfirst-degreerelativesofprobandsis2to4timeslarger
comparedtocontrols[8–12].Itisshownthatvariousgeneticfactors
account for 40–70% of the risk for developing the disorder [13].
Serotonin is one of the main neurotransmitters of the central
nervous system (CNS), and it plays an important role in psychiatric
disorders. Tryptophan hydroxylase-2 (TPH2) is the rate-limiting
enzyme in the synthetic pathway for brain serotonin and is
considered key factor for the maintainance of normal serotonin
transmission in the CNS [2,14].
In 2004, Zill et al found two SNPs in TPH2 that were associated
with MDD in Caucasians [15]. Subsequently, Zhang and
colleagues in 2005 identified the G1463A variant (rs120074175),
a rare variant with minor allele frequency ,1%, that predicted an
amino acid substitution at a highly conserved position in
tryptophan hydroxylase2 (TPH2) (p.Arg441His). When expressed
in PC12 cells, 441His shown an 80% loss in serotonin production.
Genotyping results revealed the presence of the 1463 A-allele in 9
of 87 elderly unipolar affective disorder (UP) patients (.60 years)
and in 3 of 219 healthy control individuals [16]. Interestingly, the
1463 A-allele was not replicated in subsequent follow-up studies
[17–22]. However, the important biological function of TPH2
attracted many researchers to explore a wider range of SNPs
covering exons and introns that might identify genetic risk variants
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[23,24]. The current systematic overview aims to identify probable
evidence of association of different genetic variants in TPH2 with
MDD.
Materials and Methods
Search Strategy and Selection Criteria
We scrutinized PubMed, Embase, HuGNet and China National
Knowledge Infrastructure (CNKI) using the keywords ‘major
depression’, ‘unipolar depression’, ‘major depressive disorder’,
‘MDD’, ‘tryptophanhydroxylase 29, and ‘TPH2’. Major depres-
sion was defined according to the DSM-IV-TR (American
Psychiatric Association, 2000), DSM-IIR or ICD10 and is
characterized by major depressive episodes without a history of
manic, mixed, or hypo manic episodes. A major depressive episode
is characterized by a .2 weeks period where there is a new onset
or clear worsening of either depressed mood or loss of interest or
pleasure in nearly all activities. Four additional symptoms
including changes in appetite, weight, sleep, and psychomotor
activity; decreased energy; feelings of worthlessness or guilt;
difficulty thinking, concentrating, or making decisions; or recur-
rent thoughts of death or suicidal ideation, plans, or attempts must
be also present. The episode must be accompanied by distress or
impairment in social, occupational, or other important areas of
functioning. (http://omim.org/entry/608516). The data were last
accessed on Oct 26, 2011 and we did not set any language
restrictions. The references of the retrieved articles were
independently screened by two researchers. The eligibility criteria
were: a) case- control or cohort studies that quantitatively assessed
the relationship of TPH2 gene polymorphism and risk of MDD; b)
cases with MDD were eligible regardless of age, gender and
ethnicity. Studies without data on allelic counts in cases and
controls and studies focusing on survival or other clinical outcome
in MDD were excluded from the study. In case of overlapping
cases/controls in different studies, we retained only the studies
with the largest sample size.
For each study, we recorded the first author, year of publication,
the ethnic group of the study population, the method of
genotyping, the number of genotyped cases and controls, the
source of control population, the standard errors (SE) or the 95%
confidence interval (CI), and the odds ratio (OR). Whenever ORs
and SEs or 95% CIs were not reported we calculated them from
the available data in each paper. We coined the calculated ORs in
each study so as to reflect always to the same allelic contrast.
Whenever a study included information on a negative strand we
used the complimentary allelic strand. We calculated the linkage
disequilibrium (LD) for the eligible SNPs using SNAP (http://
www.broadinstitute.org/mpg/snap/) for each relevant ethnic
population. We considered perfect proxies and therefore included
in the same meta-analyses SNPs with r
2=1 and D’=1. LD
assessement was based on the 1000 genomes panel and a distance
limit of 500 mb was set.
Meta-analysis
For each study we calculated the OR and its respective SE. The
heterogeneity of the studies was assessed using the Cochran’s Q
test (considered significant for P,0.10) and it was quantified by
the I
2 statistic [25]. I
2 ranges between 0 to 100% and it is
considered low, moderate, large and very large for values 0%
225%, 25% 250%, 50% 275% and .75% respectively. Both
fixed effects (Mantel-Haenszel) and random effects (DerSimonian
and Laird) models were used to combine the data. Random effects
are more conservative incorporating an estimate of the between-
study variance and thus provide relatively wider 95% CIs, when
heterogeneity exists. We performed a sensitivity analysis on either
Caucasians or Asians, based on the larger number of studies for a
specific ethnic group. Small vs large studies effect bias was assessed
using Harbord’s modified regression test. The analyses were
conducted with R package (http://www.R-project.org). All p
values were two sided and using Bonferroni correction for the 12
comparisons significance can be deemed at the p=0.004 level.
Results
A total of 270 abstracts met the search criteria and were
retrieved through Pubmed, EMBASE, HuGNet and CNKI
databases. Two reviewers assessed the relevant studies indepen-
dently. We identified 64 relevant studies that described the
association between the TPH2 polymorphism and MDD;
however, after scrutinizing the full articles 28 studies were eligible
for inclusion in our review and meta–analysis. Specifically 21 out
of the 64 identified articles did not meet our inclusion criteria
regarding the design of the study and, furthermore, their
description of the source of the cases and the controls was
inadequate. Moreover, 8 papers included overlapping populations,
and 7 papers used dimensional scores rather than diagnoses as an
outcome. Among the remaining 28 eligible studies, 1 article did
not provide adequate data of TPH2 polymorphisms [26]. Thus, a
total of 27 studies were included in our meta-analysis. We also
scrutinized the 19 published GWAs studies for reported informa-
tion; however we were not able to get effect estimates or allele
counts for any of our eligible SNPs. Detailed characteristics of all
studies included in the meta-analysis are listed in Table S1.
Nineteen studies included participants of European descent, 14
studies included Asians, 3 African Americans and 3 studies
participants of other descent (Native Americans and Middle
Eastern subjects. All reports selected MDD patients on the basis of
DSM-III-R, DSM-IV and all eligible articles pertained case-
control studies.
In most of the reports, cases and controls were subsequently
randomly selected. Of the eligible studies, 21 described a matched
case-control design including participants matched for age and/or
gender. 20 reports used hospital controls whereas 7 studies used
non-hospital or other types of controls. All cases had clinical
diagnosis of MDD at study entry. The detailed methods used for
determining the genotypes of TPH2 status are described in each
article. Most of the studies included in the present analyses used
genomic DNA extracted from blood but one that used brain tissue
[27].
Of the 2012 SNPs in TPH2, 74 SNPs across the TPH2 gene
area had been assessed and for 5 SNPs we were not able to identify
an rsid number. Out of the 69 SNPs that were further considered
for the analysis 50 SNPs located in introns; 13SNPs located in
exons, 6 SNPs located in 5 UTR. Forty SNPs were reported in less
than 3 studies and therefore were excluded from further
consideration. The 29 remaining SNPs were locared in 13
independent loci. We excluded rs120074175 because all subse-
quent studies reported zero counts for the minor allele in cases and
controls and therefore we were not able to calculate a robust effect
estimate [17–22,28]. Thus 28 SNPs in 12 independent loci were
included for the analysis.
Overall, the eligible studies included 13,041 cases and 11,568
controls. For all independent loci, we calculated the summary ORs
using fixed and random effects models. The results indicated that
rs4570625 was associated with MDD. An analysis of 1364 cases
and 1390 controls for rs4570625, including all ethnic groups
yielded a summary OR=0.83 (95%CI: 0.74; 0.93) (p-val-
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heterogeneity (I
2=31%, Cochran’s p-value=0.21). The random
effects summary OR was 0.84 (95% CI: 0.73; 0.96) (Figure 1). A
sensitivity analysis including 4 Asian studies shown a summary
OR=0.77 (95% CI: 0.66; 0.90) when random effects were
applied.
The summary OR for rs17110747 (1205 cases and 1331
controls) including all ethnic groups was 0.84 (95% CI: 0.73; 0.98)
(p-value=0.02, with non-statistically significant between–study
heterogeneity (I
2=21%, Cochran’s p=0.28). However the
summary OR was not statistical significant when we applied
random effects models (Figure 2). Furthermore, the results were
similar when only Asian populations were analyzed (Table S2).
There is no indication for small vs large study bias in those two
findings using the Harbord’s modified regression test with p-values
0.22 and 0.11 respectively.
All the other loci did not yield significant association between
the eligible genetic variants and MDD. One other locus
(rs11178997) produced a nominally significant result with fixed
effects models only, however the association was not present when
only Caucasian populations were considered.
Discussion
We have conducted to the best of our knowledge the first
comprehensive systematic overview of genetic studies of TPH2
and MDD. We searched all the candidate-gene studies to identify
the eligible SNPs. Furthermore we scrutinized the published
genome-wide association studies (GWAs) in the field for additional
reported information. We were able to perform meta-analyses of
12 independent loci. We found significant evidence for 2 MDD
susceptibility SNPs (rs4570625, rs17110747). It appears that
rs4570625 has strong epidemiological credibility. However, we
were not able to study most of the SNPs identified due to our
exclusion criteria that it was set to three or more studies.
Both identified SNPs shown small to moderate effect, which is
well expected in the field of genetic epidemiology. Rs4570625
remained significant after random effect calculations and the total
number of cases and controls with the least frequent genetic group
exceeds 1000 alleles. Small to moderate heterogeneity was
detected and there is no evidence of small-study effect bias and
all studies were in HWE. Overall and by applying the Venice
interim guidelines [29] that use the amount of evidence the
replication of results and the protection of bias for the evaluation
of a genetic risk variant indicates that the specific finding could be
considered of strong credibility. Rs17110747 was not replicated
using random effects models and the evidence should be
considered weak even though the observed heterogeneity was
small and no small-study effect biases were detected. Interestingly
enough this association was stronger in Asian populations but this
analysis was limited to only three studies. Therefore more robust
inferences are not allowed.
TPH2 was found to be neuronal specific and predominantly
expressed in brain serotonergic neurons originating from raphe
Figure 1. Forest plot of genetic association studies of rs4570625-T and major depression.
doi:10.1371/journal.pone.0036721.g001
Figure 2. Forest plot of genetic association studies of rs17110747-A and major depression.
doi:10.1371/journal.pone.0036721.g002
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and rs1843809 were associated with MDD in Caucasians but we
were not able to replicate those findings. However, there is
evidence that rs4570625 has an important biological function.
Inoue et al found that T allele carriers were associated with
significantly smaller volumes in bilateral amygdala and hippo-
campus and higher reward dependence than those with G allele
homozygotes [30]. There are also associations reported with other
psychiatric disorders. Zhang et al identified that rs4570625 on
TPH2 gene might play an important role in the development of
positive symptoms in Han Chinese schizophrenic patients [31] and
Kim et al reported that the specific polymorphism may has a
significant contribution in the pathogenesis of panic disorder [32].
More recently, Leppanen et al found infants with the T-carrier
genotype exhibited a significantly higher number of missing
attention shifts [33]. Regarding rs17110747, there is no significant
evidence that the specific risk variant is a loss-of-function mutation
and further studies are needed to support such a finding.
Our study has several limitations. Although we have tested for
small-study effects, publication biases cannot be entirely excluded
from retrospective meta-analysis, regardless our extensive search
in different databases. Also, for many meta-analyses the total
number of cases and controls studied was not large enough and
therefore we are underpowered to detect even moderate
associations (OR=1.2–1.5). Moreover, we were able to synthesize
results from only 2/5 of the identified studies, thus we did not
benefit from all the available information. We excluded studies
where the genotypic distribution in controls was not in Hardy-
Weinberg equilibrium or studies that did not clearly distinguish
between MDD and bipolar disease. As a consequence, there were
46 polymorphisms that were only addressed in one or two eligible
studies. However, by adopting the criterion of three or more
studies gave us the opportunity to diminish possible false positive
signals that could derive from the synthesis of a small amount of
information. Last but not least, we searched only the manuscript
and the supplementary documents of the published GWAs and
therefore we would not be able to detect any of our eligible SNPs
that did not reached pre-specified levels of significance.
Moreover, we did not exclude studies where the controls were
recruited based on different criteria. For example, we did not
distinguish between controls that had been screened for the
absence of depression and controls that were selected from the
general population or the hospital. Such differences may
significantly contribute to the heterogeneity observed in several
associations. It would be essential that individual studies report key
characteristics of their populations that would allow for the
assessment of the observed heterogeneity and the evaluation of
possible misclassification in future efforts. To provide robust and
strong epidemiologic evidence in gene-disease association studies,
harmonization of the study designs, populations and measure-
ments is of great importance and it one of the aims suggested by
the Network of Investigator Networks of the Human Genome
Epidemiology Network [34].
Our systematic meta-analysis found strong epidemiologic
credibility for rs4570625 and significant evidence but weaker
credibility for rs17110747 in TPH2. The low coverage of genetic
variants of TPH2 makes it impossible to conclude that the other
SNPs studied are not involved in MDD. Efforts are required to
standardize the methodology in research of MDD and TPH2 gene
polymorphisms and further research aiming to replicate findings in
MDD is needed.
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